Clinical and microbiological evaluation of therapy for juvenile periodontitis.
Eight patients (mean age 15.6 yrs) with severe molar-incisor bone loss and pocket formation characteristic of juvenile periodontitis were entered into a clinical protocol of three sequential stages: scaling and root planing (S/RP); S/RP concurrent with systemic tetracycline therapy (1 gm/day for 28 days); periodontal surgery concurrent with systemic tetracycline therapy. Clinical and microbiological examinations were scheduled at baseline, at 1 to 2 months after Stage I, at 1 to 2 months after completion of tetracycline therapy in Stages II and III, and during recall. A decision to progress to the next stage or to place the patient on a 3-month recall was based solely on clinical findings (suppuration, bleeding upon probing and pocket depth) at the deepest site in each patient. Paperpoint subgingival plaque samples from representative affected sites were analyzed for percentage of total cultivable microflora composed of black-pigmented Bacteroides species (BPB), surface translocating bacteria (STB) and Actinobacillus actinomycetemcomitans (Aa). At baseline, all sites bled to probing, seven of eight sites showed suppuration, and deepest pocket depths averaged 8.0 mm. STB were detected in one and BPB in four sites, respectively, and all sites demonstrated Aa, which constituted approximately 40% of the total cultivable flora. S/RP alone had essentially no effect on either clinical or microbiological findings, and all patients progressed to Stage II. Five went on to Stage III. S/RP with tetracycline was clinically and microbiologically more effective at sites in which Aa was predominant. Surgery was required in all sites containing high levels of both BPB and Aa. These results suggest that microbiological diagnosis may be useful in selecting and monitoring treatment for juvenile periodontitis.
D000188:Actinobacillus / Q000302:isolation & purification; D000293:Adolescent; D000328:Adult; D010520:Aggressive Periodontitis / Q000382:microbiology / Q000473:pathology / Q000628:therapy*; D000543:Alveoloplasty; D001419:Bacteria / Q000302:isolation & purification; D001439:Bacteroides / Q000302:isolation & purification; D002648:Child; D003131:Combined Modality Therapy; D012534:Dental Scaling; D005260:Female; D005884:Gingival Hemorrhage / Q000175:diagnosis; D006801:Humans; D008297:Male; D010510:Periodontal Diseases / Q000628:therapy*; D013492:Suppuration; D013752:Tetracycline / Q000627:therapeutic use; D014092:Tooth Root / Q000601:surgery
D013752:Tetracycline